A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Latest Information Update: 19 Jun 2025
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Raludotatug deruxtecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 11 Apr 2025 Planned initiation date changed from 27 Mar 2025 to 11 Apr 2025.
- 03 Apr 2025 Status changed from not yet recruiting to recruiting.
- 03 Mar 2025 New trial record